Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 133

1.

Precursor States of Brain Tumor Initiating Cell Lines Are Predictive of Survival in Xenografts and Associated with Glioblastoma Subtypes.

Cusulin C, Chesnelong C, Bose P, Bilenky M, Kopciuk K, Chan JA, Cairncross JG, Jones SJ, Marra MA, Luchman HA, Weiss S.

Stem Cell Reports. 2015 Jul 14;5(1):1-9. doi: 10.1016/j.stemcr.2015.05.010. Epub 2015 Jun 18.

2.

Comparative genomic and genetic analysis of glioblastoma-derived brain tumor-initiating cells and their parent tumors.

Davis B, Shen Y, Poon CC, Luchman HA, Stechishin OD, Pontifex CS, Wu W, Kelly JJ, Blough MD; Terry Fox Research Institute Glioblastoma Consortium.

Neuro Oncol. 2016 Mar;18(3):350-60. doi: 10.1093/neuonc/nov143. Epub 2015 Aug 5.

3.

Protein kinase CK2 is important for the function of glioblastoma brain tumor initiating cells.

Rowse AL, Gibson SA, Meares GP, Rajbhandari R, Nozell SE, Dees KJ, Hjelmeland AB, McFarland BC, Benveniste EN.

J Neurooncol. 2017 Apr;132(2):219-229. doi: 10.1007/s11060-017-2378-z. Epub 2017 Feb 8.

4.

Dual mTORC1/2 blockade inhibits glioblastoma brain tumor initiating cells in vitro and in vivo and synergizes with temozolomide to increase orthotopic xenograft survival.

Luchman HA, Stechishin OD, Nguyen SA, Lun XQ, Cairncross JG, Weiss S.

Clin Cancer Res. 2014 Nov 15;20(22):5756-67. doi: 10.1158/1078-0432.CCR-13-3389. Epub 2014 Oct 14.

5.

Side population is not necessary or sufficient for a cancer stem cell phenotype in glioblastoma multiforme.

Broadley KW, Hunn MK, Farrand KJ, Price KM, Grasso C, Miller RJ, Hermans IF, McConnell MJ.

Stem Cells. 2011 Mar;29(3):452-61. doi: 10.1002/stem.582.

6.

Lipid metabolism enzyme ACSVL3 supports glioblastoma stem cell maintenance and tumorigenicity.

Sun P, Xia S, Lal B, Shi X, Yang KS, Watkins PA, Laterra J.

BMC Cancer. 2014 Jun 4;14:401. doi: 10.1186/1471-2407-14-401.

7.

Molecular heterogeneity in a patient-derived glioblastoma xenoline is regulated by different cancer stem cell populations.

Garner JM, Ellison DW, Finkelstein D, Ganguly D, Du Z, Sims M, Yang CH, Interiano RB, Davidoff AM, Pfeffer LM.

PLoS One. 2015 May 8;10(5):e0125838. doi: 10.1371/journal.pone.0125838. eCollection 2015. Erratum in: PLoS One. 2015;10(12):e0145052.

8.

Treating brain tumor-initiating cells using a combination of myxoma virus and rapamycin.

Zemp FJ, Lun X, McKenzie BA, Zhou H, Maxwell L, Sun B, Kelly JJ, Stechishin O, Luchman A, Weiss S, Cairncross JG, Hamilton MG, Rabinovich BA, Rahman MM, Mohamed MR, Smallwood S, Senger DL, Bell J, McFadden G, Forsyth PA.

Neuro Oncol. 2013 Jul;15(7):904-20. doi: 10.1093/neuonc/not035. Epub 2013 Apr 12.

9.

Mesenchymal stem cells from human fat engineered to secrete BMP4 are nononcogenic, suppress brain cancer, and prolong survival.

Li Q, Wijesekera O, Salas SJ, Wang JY, Zhu M, Aprhys C, Chaichana KL, Chesler DA, Zhang H, Smith CL, Guerrero-Cazares H, Levchenko A, Quinones-Hinojosa A.

Clin Cancer Res. 2014 May 1;20(9):2375-87. doi: 10.1158/1078-0432.CCR-13-1415.

10.

Multiple Subsets of Brain Tumor Initiating Cells Coexist in Glioblastoma.

Rennert RC, Achrol AS, Januszyk M, Kahn SA, Liu TT, Liu Y, Sahoo D, Rodrigues M, Maan ZN, Wong VW, Cheshier SH, Chang SD, Steinberg GK, Harsh GR, Gurtner GC.

Stem Cells. 2016 Jun;34(6):1702-7. doi: 10.1002/stem.2359. Epub 2016 Mar 28.

11.

Dissecting inherent intratumor heterogeneity in patient-derived glioblastoma culture models.

Teng J, Carla da Hora C, Kantar RS, Nakano I, Wakimoto H, Batchelor TT, Chiocca EA, Badr CE, Tannous BA.

Neuro Oncol. 2017 Jun 1;19(6):820-832. doi: 10.1093/neuonc/now253.

12.

An RNAi screen identifies TRRAP as a regulator of brain tumor-initiating cell differentiation.

Wurdak H, Zhu S, Romero A, Lorger M, Watson J, Chiang CY, Zhang J, Natu VS, Lairson LL, Walker JR, Trussell CM, Harsh GR, Vogel H, Felding-Habermann B, Orth AP, Miraglia LJ, Rines DR, Skirboll SL, Schultz PG.

Cell Stem Cell. 2010 Jan 8;6(1):37-47. doi: 10.1016/j.stem.2009.11.002.

13.

DNER, an epigenetically modulated gene, regulates glioblastoma-derived neurosphere cell differentiation and tumor propagation.

Sun P, Xia S, Lal B, Eberhart CG, Quinones-Hinojosa A, Maciaczyk J, Matsui W, Dimeco F, Piccirillo SM, Vescovi AL, Laterra J.

Stem Cells. 2009 Jul;27(7):1473-86. doi: 10.1002/stem.89.

14.

On-target JAK2/STAT3 inhibition slows disease progression in orthotopic xenografts of human glioblastoma brain tumor stem cells.

Stechishin OD, Luchman HA, Ruan Y, Blough MD, Nguyen SA, Kelly JJ, Cairncross JG, Weiss S.

Neuro Oncol. 2013 Feb;15(2):198-207. doi: 10.1093/neuonc/nos302. Epub 2012 Dec 21.

15.

ING5 activity in self-renewal of glioblastoma stem cells via calcium and follicle stimulating hormone pathways.

Wang F, Wang AY, Chesnelong C, Yang Y, Nabbi A, Thalappilly S, Alekseev V, Riabowol K.

Oncogene. 2018 Jan 18;37(3):286-301. doi: 10.1038/onc.2017.324. Epub 2017 Sep 18.

16.

ADAM-9 is a novel mediator of tenascin-C-stimulated invasiveness of brain tumor-initiating cells.

Sarkar S, Zemp FJ, Senger D, Robbins SM, Yong VW.

Neuro Oncol. 2015 Aug;17(8):1095-105. doi: 10.1093/neuonc/nou362. Epub 2015 Feb 1.

17.

Multiplexed RNAi therapy against brain tumor-initiating cells via lipopolymeric nanoparticle infusion delays glioblastoma progression.

Yu D, Khan OF, Suvà ML, Dong B, Panek WK, Xiao T, Wu M, Han Y, Ahmed AU, Balyasnikova IV, Zhang HF, Sun C, Langer R, Anderson DG, Lesniak MS.

Proc Natl Acad Sci U S A. 2017 Jul 25;114(30):E6147-E6156. doi: 10.1073/pnas.1701911114. Epub 2017 Jul 10.

18.

miR-124 and miR-137 inhibit proliferation of glioblastoma multiforme cells and induce differentiation of brain tumor stem cells.

Silber J, Lim DA, Petritsch C, Persson AI, Maunakea AK, Yu M, Vandenberg SR, Ginzinger DG, James CD, Costello JF, Bergers G, Weiss WA, Alvarez-Buylla A, Hodgson JG.

BMC Med. 2008 Jun 24;6:14. doi: 10.1186/1741-7015-6-14.

19.

Krüppel-like family of transcription factor 9, a differentiation-associated transcription factor, suppresses Notch1 signaling and inhibits glioblastoma-initiating stem cells.

Ying M, Sang Y, Li Y, Guerrero-Cazares H, Quinones-Hinojosa A, Vescovi AL, Eberhart CG, Xia S, Laterra J.

Stem Cells. 2011 Jan;29(1):20-31. doi: 10.1002/stem.561.

20.

A molecular screening approach to identify and characterize inhibitors of glioblastoma stem cells.

Visnyei K, Onodera H, Damoiseaux R, Saigusa K, Petrosyan S, De Vries D, Ferrari D, Saxe J, Panosyan EH, Masterman-Smith M, Mottahedeh J, Bradley KA, Huang J, Sabatti C, Nakano I, Kornblum HI.

Mol Cancer Ther. 2011 Oct;10(10):1818-28. doi: 10.1158/1535-7163.MCT-11-0268. Epub 2011 Aug 22.

Supplemental Content

Support Center